Quoin Pharmaceuticals Ltd. announced on January 14, 2025 further positive clinical data from its ongoing pediatric Netherton Syndrome study. After six weeks of dosing in Quoin?s ongoing 12-week Investigator Pediatric Study, a significant improvement was observed in the skin area treated with QRX003 versus the non-treated area. Specifically, at baseline prior to dosing with QRX003, the IGA assessment of the subject?s skin was classified as ?severe.?
After 12 days of dosing, the IGA assessment of the subject?s skin was classified as ?mild-moderate.? Now, after six weeks of dosing twice a day, the IGA assessment of the subject?s skin was classified as ?Mild.? As a result of these positive results, the subject is being transitioned to having QRX003 applied to their whole body surface area (BSA) as opposed to the approximately 20% of their BSA that was being tested for the initial six weeks.
In addition, there have been no adverse events or safety concerns reported to date for this subject, which is consistent with observations from each of Quoin?s ongoing clinical studies in Netherton Syndrome subjects.
